Regulatory Information

Rare Pediatric Disease Priority Review Vouchers, Draft Guidance for Industry

November 17, 2014

PDF Printer Version

This guidance provides information on the implementation of section 908 of the Food and Drug Administration Safety and Innovation Act (FDASIA), which added section 529 to the Federal Food, Drug, and Cosmetic Act (the FD&C Act). Under section 529, FDA will award priority review vouchers to sponsors of certain rare pediatric disease product applications that meet the criteria specified in that section.

FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.

Page Last Updated: 01/15/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.